doi: 10.1056/NEJMoa2204601 24 SmitsMMVan RaalteDH
Glucagon-like peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis
Pipeline Expansion into Cardiovascular and Liver Diseases Signals Market Diversification Beyond diabetes and obesity, researchers are actively evaluating GLP-1 receptor agonists in other metabolic and cardiovascular conditions
1st-line maintenance antiseizure medication: levetiracetam Levetiracetam is increasingly being utilized as a front-line antiseizure medication
Accordingly, incretin-based therapies, such as DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) that are resistant to degradation by DPP-4, have been introduced in the market within the past decade to overcome and extend the short half-life of the incretin effect
Severe L-carnitine deficiency caused by certain genetic defects leads to altered levels of fuel sources in the blood, including low ketones, low blood sugar, high ammonia
